Serina Therapeutics, Inc.

SER

AMEXHealthcareBiotechnology

Open in GoAI

Regular session

$2.82

−$0.05 · -1.74%

Aug 24, 10:15 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

27/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Overpriced

Momentum

Weakening

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Steven A. Ledger
Listed since: Nov 28, 2018
Employees: 16